Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PD-L1 inhibitors

- PMLiVE

FDA bars generic version of Purdue’s painkiller OxyContin

New abuse-deterrent formulation means original version no longer has positive benefit-to-risk profile

- PMLiVE

BMS plans major expansion of Orencia plant

Will invest $250m in biologics manufacturing facility

Merck & Co’s Jürgen Polifka joins Cardiome

Will lead commercialisation in Europe of atrial fibrillation treatment Brinavess

- PMLiVE

Merck & Co fails to block generic Januvia in India

Court says Glenmark can sell cheap copy of diabetes drug

- PMLiVE

BMS names Francis Cuss as new R&D chief

Will replace Elliott Sigal who retires

- PMLiVE

AstraZeneca hit by US Pulmicort patent ruling

Federal court says patent for inhaled steroid drug is invalid

- PMLiVE

Novartis says Indian Glivec verdict “discourages innovation”

Country's Supreme Court denies the cancer drug patent protection

Novartis building

Pharma waits for Glivec patent verdict in India

Intellectual property decision could have far-reaching consequences for industry

- PMLiVE

AstraZeneca settles with generic rivals in Crestor patent challenge

Blocks competition in US until May 2016

Biogen Idec building

Biogen wins extra patent protection for MS drug Tecfidera

Dosing patent provides exclusivity until 2028

- PMLiVE

AstraZeneca cuts 1,600 jobs in overhaul of global operations

US and UK affected as Soriot pushes ahead with R&D restructuring

- PMLiVE

Bayer sues Glenmark over its skin disorder generic

India-based firm files for US approval of its version of Finacea

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links